COVID-19 patients improve after experimental heart cell therapy
Four of six critically ill COVID-19 (coronavirus) patients significantly improved after receiving an experimental therapeutic designed to reduce inflammation, a major cause of death from this disease, according to a case series published by Cedars-Sinai and Capricor Therapeutics.
.png)
No hay comentarios:
Publicar un comentario